Overview

A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
0
Participant gender:
All
Summary
REaCT-5G will compare bone pain from a single dose of Pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adjuvant chemotherapy.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Treatments:
Lenograstim
Criteria
Inclusion Criteria:

- Patients with early-stage or locally-advanced breast cancer receiving neoadjuvant or
adjuvant chemotherapy requiring primary febrile neutropenia prophylaxis with G-CSF

- Able to provide verbal consent

- Able to complete questionnaires in English or French

Exclusion Criteria:

- No access to pegfilgrastim or filgrastim prior to randomization

- Metastatic cancer

- Known hypersensitivity to filgrastim or pegfilgrastim or one of its components